Your browser is no longer supported. Please, upgrade your browser.
Settings
ACIU AC Immune SA daily Stock Chart
ACIU [NASD]
AC Immune SA
Index- P/E- EPS (ttm)-0.50 Insider Own60.88% Shs Outstand66.81M Perf Week-5.87%
Market Cap825.10M Forward P/E- EPS next Y-1.06 Insider Trans0.00% Shs Float22.44M Perf Month34.53%
Income-28.50M PEG- EPS next Q-0.23 Inst Own22.40% Short Float7.17% Perf Quarter40.34%
Sales19.70M P/S41.88 EPS this Y-226.60% Inst Trans- Short Ratio21.39 Perf Half Y-8.38%
Book/sh1.84 P/B6.71 EPS next Y-4.70% ROA-22.50% Target Price22.90 Perf Year43.44%
Cash/sh1.64 P/C7.54 EPS next 5Y- ROE-25.00% 52W Range6.03 - 16.35 Perf YTD-3.52%
Dividend- P/FCF- EPS past 5Y- ROI-19.20% 52W High-24.49% Beta-
Dividend %- Quick Ratio13.60 Sales past 5Y- Gross Margin- 52W Low104.81% ATR1.11
Employees86 Current Ratio13.60 Sales Q/Q-25.00% Oper. Margin- RSI (14)55.82 Volatility14.37% 8.83%
OptionableNo Debt/Eq0.00 EPS Q/Q-21.70% Profit Margin- Rel Volume3.19 Prev Close13.77
ShortableYes LT Debt/Eq0.00 EarningsAug 08 BMO Payout- Avg Volume75.21K Price12.35
Recom1.50 SMA2014.59% SMA5019.79% SMA2009.22% Volume230,012 Change-10.31%
Apr-05-18Initiated H.C. Wainwright Buy $18
Mar-23-18Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Outperform
Oct-18-16Initiated Jefferies Buy $25
Oct-18-16Initiated Credit Suisse Outperform $18
Jul-17-18 04:01AM  Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Technology Platforms to be presented at AAIC in Chicago GlobeNewswire
Jul-06-18 07:19AM  AC Immune Announces Results of Annual General Meeting GlobeNewswire +38.28%
Jun-08-18 07:55AM  Research Report Identifies AC Immune SA, Vipshop, Infosys, STMicroelectronics N.V., BRF S.A., and National Steel with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
May-02-18 06:50PM  What Does AC Immune SAs (NASDAQ:ACIU) Ownership Structure Look Like? Simply Wall St.
08:43AM  Moving Average Crossover Alert: AC Immune SA (ACIU) Zacks
04:00AM  AC Immune Reports First Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Apr-27-18 04:31PM  AC Immune Announces Results of Extraordinary Shareholders Meeting GlobeNewswire
Apr-20-18 03:54PM  Will AC Immune SAs (NASDAQ:ACIU) Earnings Grow Over The Next Few Years? Simply Wall St.
Apr-05-18 04:01AM  AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease GlobeNewswire -11.11%
Apr-03-18 07:20AM  Wired News MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine Dependence ACCESSWIRE +12.49%
Mar-27-18 08:30AM  Investor Expectations to Drive Momentum within Ambev S.A, AC Immune SA, Comp En De Mn Cemig ADS, GSV Capital, Novartis AG, and New York Discovering Underlying Factors of Influence GlobeNewswire
Mar-23-18 11:59AM  AC Immune Promising On Alzheimer's, But Light On Short-Term Catalysts, Says Credit Suisse Benzinga -9.12%
Mar-20-18 05:21PM  AC Immune posts 4Q profit Associated Press
05:00AM  AC Immune reports full-year 2017 financial results - successful first year as a public company GlobeNewswire
Mar-15-18 05:00AM  AC Immune prepares for a first in human study of a promising positron emission tomography (PET) tracer for Parkinson's disease GlobeNewswire
Feb-06-18 08:31AM  AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference GlobeNewswire
Dec-27-17 08:37AM  AC Immune SA :ACIU-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-18-17 05:25PM  AC Immune SA (NASDAQ:ACIU) And The Healthcare Industry Prospect For 2017 Simply Wall St.
Dec-01-17 02:20PM  AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases GlobeNewswire
Nov-28-17 07:50AM  AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : November 28, 2017 Capital Cube
Nov-24-17 12:25PM  AC Immune SA (ACIU): Financial Strength Analysis Simply Wall St.
Nov-21-17 08:32AM  AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases GlobeNewswire +13.11%
Nov-16-17 12:25PM  AC Immune SA Value Analysis (NASDAQ:ACIU) : November 16, 2017 Capital Cube
Nov-15-17 07:49AM  AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : November 15, 2017 Capital Cube
Nov-13-17 04:35PM  AC Immune reports 3Q loss Associated Press
06:48AM  AC Immune SA Reports Third Quarter 2017 Financial Results and Corporate Update GlobeNewswire
Nov-02-17 06:23AM  AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into Phase 2 Trial for Alzheimer's Disease GlobeNewswire
Oct-24-17 05:41AM  AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference GlobeNewswire
Oct-03-17 04:55AM  AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinson's Research GlobeNewswire
Sep-12-17 06:05AM  AC IMMUNE COMPLETES RECRUITMENT FOR LOW-DOSE COHORT IN WORLD'S FIRST CLINICAL TRIAL FOR ANTI-ABETA VACCINE TARGETING ALZHEIMER'S DISEASE-LIKE CHARACTERISTICS IN INDIVIDUALS WITH DOWN SYNDROME GlobeNewswire
Sep-05-17 09:44AM  AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : September 5, 2017 Capital Cube
Aug-29-17 09:32PM  AC Immune SA Value Analysis (NASDAQ:ACIU) : August 30, 2017 Capital Cube
Aug-24-17 07:00AM  Corporate News Blog - Moleculin Biotech to Meet European Medicines Agency; Discussion on Clinical Trial Authorization for the Treatment of Acute Myeloid Leukemia ACCESSWIRE
Aug-23-17 08:51AM  AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : August 23, 2017 Capital Cube
Aug-22-17 10:37AM  AC IMMUNE DISCOVERS NEXT-GENERATION ANTIBODIES FOCUSED ON NEURODEGENERATIVE DISEASES GlobeNewswire +5.77%
Aug-09-17 06:45AM  AC IMMUNE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS GlobeNewswire
Jul-10-17 07:56AM  AC IMMUNE PROVIDES SEVEN UPDATES ON ITS PIPELINE AND TECHNOLOGY AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE GlobeNewswire
Jun-28-17 07:40AM  AC IMMUNE ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING GlobeNewswire
Jun-26-17 08:38AM  AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : June 26, 2017 Capital Cube
Jun-09-17 09:21AM  AC Immune SA :ACIU-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017 Capital Cube
May-22-17 04:37AM  AC IMMUNE AND ESSEX BIO-TECHNOLOGY ANNOUNCE RESEARCH COLLABORATION FOR NEURODEGENERATIVE DISEASES AND NEUROINFLAMMATION GlobeNewswire
May-11-17 07:08AM  AC Immune reports 1Q loss Associated Press
06:14AM  AC IMMUNE SA REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS GlobeNewswire
Apr-03-17 06:03AM  Piramal Imaging and AC Immune present first clinical data for tau PET-imaging tracer at International Alzheimer's Conference GlobeNewswire
Mar-23-17 12:23PM  AC Immune SA :ACIU-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017 Capital Cube
12:23PM  AC Immune SA :ACIU-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017
11:59AM  AC IMMUNE PROVIDES TWELVE UPDATES ON ITS PIPELINE AT THE INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES GlobeNewswire
10:41AM  AC Immune SA :ACIU-US: Earnings Analysis: 2016 By the Numbers : March 23, 2017
Mar-17-17 06:37AM  AC IMMUNE REPORTS FULL YEAR 2016 FINANCIAL RESULTS AND R&D UPDATE GlobeNewswire
Mar-07-17 09:02AM  AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : March 7, 2017 Capital Cube -8.00%
09:02AM  AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : March 7, 2017
Feb-28-17 03:15AM  Roche to start new trial of AC Immune drug against Alzheimer's Reuters
02:02AM  AC IMMUNE PARTNER GENENTECH TO START SECOND PHASE 3 CLINICAL TRIAL FOR ALZHEIMER'S THERAPY CRENEZUMAB GlobeNewswire
Jan-16-17 07:40AM  AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : January 16, 2017 Capital Cube
07:40AM  AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : January 16, 2017
Jan-05-17 08:11AM  AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : January 5, 2017
Dec-23-16 09:16AM  AC Immune SA Value Analysis (NASDAQ:ACIU) : December 23, 2016 Capital Cube +5.33%
09:16AM  AC Immune SA Value Analysis (NASDAQ:ACIU) : December 23, 2016
Dec-22-16 07:24AM  AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : December 22, 2016
Dec-13-16 02:08AM  Here is What Hedge Funds Think About AC Immune Ltd (ACIU) at Insider Monkey
Dec-12-16 07:22AM  AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : December 12, 2016 -13.80%
Dec-09-16 03:52PM  AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER'S THERAPY CRENEZUMAB GlobeNewswire +23.90%
12:55PM  Biogen gains on new Eli Lilly Alzheimers data, as beta-amyloid hypothesis lives to see another day at MarketWatch
08:22AM  Astra, Lilly stick with Alzheimer's approach despite setback
Nov-23-16 04:28PM  What Eli Lillys hard fall in Alzheimers treatment race means for its competitors at MarketWatch -15.84%
09:35AM  AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF FINANCIAL OFFICER GlobeNewswire
Nov-18-16 10:02AM  AC Immune SA :ACIU-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 -5.03%
07:48AM  Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know
Nov-15-16 07:41AM  AC Immune SA announces results of annual general meeting GlobeNewswire
Nov-11-16 07:12AM  AC Immune Reports Third Quarter 2016 Results GlobeNewswire +6.78%
Oct-18-16 11:05AM  Apptio and AC Immune Get Mixed Post-IPO Analyst Coverage at End of Quiet Period +5.27%
07:37AM  Alzheimer's Remains a Top Priority for Big Pharma at Motley Fool
06:19AM  Coverage initiated on AC Immune by Jefferies, Credit Suisse and Leerink Partners
Sep-28-16 04:14PM  AC Immune SA: Price momentum supported by strong fundamentals +5.99%
07:32AM  Heres A Look At AC Immune Ltd (ACIU)s Alzheimers Candidate, Crenezumab at Insider Monkey
Sep-27-16 08:19AM  Biotech IPOs: Outliers, Value Creation And The Dispersion Of Returns at Forbes +10.36%
Sep-23-16 03:25PM  [$$] Companies Take Advantage of Narrow IPO Window at The Wall Street Journal
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Essex Bio-Technology Limited, as well as Nestle Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.